|Bid||0.0000 x 2900|
|Ask||0.0000 x 1100|
|Day's Range||0.6715 - 0.7038|
|52 Week Range||0.6500 - 3.2600|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Celldex Therapeutics Inc (NASDAQ:CLDX), a US$104.06M small-cap, is a healthcare company operating in an industry, which faces demand for new drug development to meet new or persistent chronic illnesses, andRead More...
Celldex (CLDX) reports wider-than-expected loss in Q1 but sales beat estimates. It discontinues development of its lead pipeline candidate following its failure in breast cancer study.
The Hampton, New Jersey-based company said it had a loss of 84 cents per share. Losses, adjusted for asset impairment costs, came to 19 cents per share. The results fell short of Wall Street expectations. ...
The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.
Celldex Therapeutics' (CLDX) glembatumumab vedotin fails to meet primary endpoint in phase IIb METRIC study in metastatic breast cancer.
Shares of Celldex Therapeutics Inc. plummeted 40% in premarket trade Monday toward a record low, after the drug maker said a phase 2b trial of its treatment of triple-negative breast cancer failed to meet ...
Today I will take a look at Celldex Therapeutics Inc’s (NASDAQ:CLDX) most recent earnings update (31 December 2017) and compare these latest figures against its performance over the past fewRead More...
Celldex Therapeutics Inc’s (NASDAQ:CLDX): Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. The US$331.52M market-cap company announced aRead More...
Since Celldex Therapeutics Inc (NASDAQ:CLDX) released its earnings in December 2017, analyst consensus outlook seem pessimistic, as a -27.84% fall in profits is expected in the upcoming year. Though thisRead More...
Celldex (CLDX) reports narrower-than-expected loss in Q4 with sales also beating estimates. Moreover, shares rise in after-hours trading on Mar 7 following the results.